<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947061</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-033</org_study_id>
    <nct_id>NCT02947061</nct_id>
  </id_info>
  <brief_title>S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer</brief_title>
  <official_title>S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer: a Phase 2, Prospective,Multicenter, Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the progression free survival(PFS) and safety of TS-S vs. TX-X in Patients With&#xD;
      Advanced Breast Cancer first-line treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare progression free survival (PFS) of the S-1 combined with docetaxel followed by&#xD;
      maintenance treatment with S-1 and capecitabine combined with docetaxel followed by&#xD;
      maintenance therapy with capecitabine in patients with advanced breast cancer first-line&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1 plus Docetaxel</intervention_name>
    <description>S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1</description>
    <arm_group_label>test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine plus Docetaxel</intervention_name>
    <description>Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 ≤ age ≤ 75;&#xD;
&#xD;
          -  ECOG 0-2, The expected survival time more than 3 months;&#xD;
&#xD;
          -  Histologically or cytologically proven locally advanced or advanced HER-2 negative&#xD;
             breast cancer;&#xD;
&#xD;
          -  No chemical treatment after Cancer recurrence;&#xD;
&#xD;
          -  At least one measurable disease ( as per RECIST1.1);&#xD;
&#xD;
          -  Adequate bone marrow functions (ANC ≥1.5×109 /L, PLT ≥100×109 /L, HB ≥90 g/L);&#xD;
&#xD;
          -  Adequate renal functions(serum creatinine ≤ 1.5 ULN; creatinine clearance≥50 ml/min);&#xD;
&#xD;
          -  liver functions (serum bilirubin ≤ 1.5ULN, AST/ALT ≤ 2.5 ULN);&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
          -  Pregnancy test (serum or urine) within 7 days of entry and willing to use the&#xD;
             appropriate method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously chemotherapy with cytotoxic drugs&#xD;
&#xD;
          -  Pregnant, lactating women Did not take effective contraceptive measures&#xD;
&#xD;
          -  Adjuvant chemotherapy/ neoadjuvant chemotherapy with 5-FU-based chemotherapy or&#xD;
             Paclitaxel -based chemotherapy within 1 year after recurrence;&#xD;
&#xD;
          -  Her-2 positive or unknown&#xD;
&#xD;
          -  Other trails Before 4weeks&#xD;
&#xD;
          -  Affection of the absorption of drugs(Unable to swallow、after gastrectomy、Chronic&#xD;
             diarrhea and intestinal obstruction&#xD;
&#xD;
          -  Organs with rapid progression of invasion(Liver and lung lesions more than 1/2 organ&#xD;
             area or hepatic insufficiency)&#xD;
&#xD;
          -  Central nervous system disorders or mental disorders&#xD;
&#xD;
          -  For docetaxel or fluorouracil or Twain 80 had serious adverse reactions or Allergy to&#xD;
             5-FU&#xD;
&#xD;
          -  Severe upper gastrointestinal ulcer or absorption dysfunction syndrome&#xD;
&#xD;
          -  Abnormal blood routine (ANC &lt;1.5×109 /L, PLT &lt;100×109 /L, HB &lt;90 g/L);&#xD;
&#xD;
          -  Renal functions(serum creatinine &gt; 1.5 ULN);&#xD;
&#xD;
          -  Liver functions (serum bilirubin &gt; 1.5ULN&#xD;
&#xD;
          -  Brain metastases out of control&#xD;
&#xD;
          -  Other unapplicable&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guohui Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tumor Hospital of Shanxi Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binghe Xu, M.D.</last_name>
    <phone>010-87778826</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiayu Wang, M.D.</last_name>
    <phone>010-87778826</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>No.17 panjiayuannanli, Chaoyang District</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghe Xu, M.D.</last_name>
      <phone>86-10-88788826</phone>
      <email>xubinghe@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jiayu Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>Professor and Director, Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Advanced Breast Cancer,first treatment, S1, Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

